Abstract 3512
Background
Eribulin (Halaven®; Eisai Co., Tokyo, Japan) is a synthetic analogue of halichondrin B that was approved for advanced liposarcoma. Eribulin, besides its well stablished cytotoxic activity, induces vascular remodelling and increased tumor perfusion, as well as inhibits pericyte- and endothelial-driven angiogenesis, which could facilitate the distribution of other drugs within the tumor. Altogether, we hypothesize that eribulin and gemcitabine, acting in different cell cycle phases and modulating distintly tumour microenvironment, could be synergistic, without overlapping toxicity.
Methods
CP0024 human leiomyosarcoma primary cell line, SK-UT-1 human leiomyosarcoma cell line and, 93T449 and 94T778 human liposarcoma cell lines were treated with increased concentrations of eribulin (1x10-7M to 1x10-11M) or gemcitabine (1x10-9M to 1x10-13M) to determine IC50 values. Combination index values of eribulin plus gemcitabine were calculated, after treating L-sarcoma cell lines with both drugs using the following administration sequences: concomitant (E+G), eribulin followed by gemcitabine (E→G) and gemcitabine followed by eribulin (G→E). Cell viability, at 72 hours, was measured by MTS cell proliferation assay.
Results
The IC50 values determined for eribulin ranged between 0.28nM (SK-UT-1) and 1.98nM (94T778), while IC50 values of gemcitabine ranged between 2.10nM (SK-UT-1) and 7.02nM (94T778). The combination index values at ED50 (the effective doses at which 50% of cell killing occurred) ranged: between 0.27 (SK-UT-1) and 0.89 (94T778), when cell lines were treated with E+G; between <0.10 (SK-UT-1) and 0.33 (CP0024) when treated with G→E; and between <0.10 (SK-UT-1) and 0.20 (CP0024) when cells were treated with E→G. All the cell lines showed a higher synergism when treated using the E→G administration sequence.
Conclusions
Eribulin and gemcitabine combination is synergic in L-sarcoma cell lines. The administration of eribulin, followed by gemcitabine is the recommended administration sequence for further studies. The mechanisms underlying eribulin plus gemcitabine synergy, as well as predictive biomarkers of response to the combination, will be evaluated in in vitro and in vivo models of L-sarcoma.
Clinical trial identification
Legal entity responsible for the study
Instituto de Biomedicina de Sevilla.
Funding
Eisai Co., Ltd.
Editorial Acknowledgement
Disclosure
D.S. Moura: Corporate-sponsored research fees: Eisai. Co. Ltd. J. Martin-Broto: Corporate-sponsored research fees: Eisai. Co., Ltd., Novartis, PharmaMar; Honoraria or consultation fees: Lilly, Novartis, PharmaMar; Company sponsored speaker’s bureau: PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract